Opko Health stock soars on $722M BioReference asset sale
Opko Health (OPK) shares rose 20% premarket after Labcorp (LH) agreed to buy BioReference Health assets for $722M, with up to $150M more in earnouts. The deal includes the 4Kscore Test, with expected first-year revenue of $250M. OPKO plans to focus on biopharmaceuticals. The transaction awaits regulatory approval.
How this was made
The 30-second read
Why it matters
The deal provides Opko with cash to fund drug development, while Labcorp gains a proprietary prostate cancer test.
Market read
A significant M&A transaction driving a 20% pre‑market rally in Opko and modest outlook for Labcorp.
What to watch
Potential regulatory scrutiny of the 4Kscore test's market expansion.
Background
Opko Health is refocusing on its biopharma pipeline after divesting its laboratory testing business to Labcorp.
Ticker impact
Opko Health shares jumped 20% pre‑market after Labcorp agreed to buy select BioReference assets for $722M.
upward pressure as the market prices in the cash infusion and strategic refocus.
The deal provides immediate liquidity and removes non‑core assets, which investors view favorably.
Labcorp announced the acquisition of BioReference Health assets for $722M, adding the 4Kscore test to its portfolio.
modest upside as the acquisition is priced at market rates and may be accretive over time.
The transaction size is modest relative to Labcorp's market cap; impact will be gradual.
Market effects
Consolidation in the clinical laboratory sector may pressure peers to consider similar acquisitions.
U.S. healthcare services market sees a boost in M&A activity.
Limited to U.S. biotech and diagnostics firms.
Counterpoint
The cash outlay could strain Labcorp's balance sheet if integration costs exceed expectations.
Key entities
- CompanyOpko Health Inc
Seller of BioReference assets, ticker OPK.
- CompanyLabcorp Holdings Inc
Buyer of BioReference assets, ticker LH.
